Biotechnology stocks can be a great choice to increase your portfolio growth. These corporate laboratories include interesting research, and in some cases games change treatment candidates are approaching important stages or even passing through the finish line. As an investor in these companies, you can use it as they report positive clinical trial news, to evaluate regulatory approval or to start earnings from the product.
Wall Street currently believes that two candidates are particularly convincing, predicting that more than 80% and 200% will increase in the next 12 months. One of these players is working in a rapidly growing weight loss medicine, while the other candidate showed his strengths to win the world’s first product confirmation based on CRISPR gene editing. Let’s review these two biotechnology campaigns you want to buy before it is fast.
Image Source: Getty Images.
Viking Therapeutics(Nasdaq: VKTX) Early last year, it increased when she reported solid data from phase 2 candidate for weight loss, VK2735, but has since gave the campaign that profit and traded closer to the level it was before that report.
Since then, the company has continued to improve the VK2735 injection form and tablet version, and the demand for this type of drug remains high – these are two reasons to believe that Viking can start again. And catalysts can be on the horizon.
The drug works similarly to Eli LillyBlockBuster Tyzepatide, sold by Mounjar and Zepbound. These drugs interact with digestive hormones and helped people lose weight quickly and safely. Viking launches the VK2735 Phase 3 test in the second quarter and expects the second half to be data from the 2 phase test tablets. Any data reports can lead to major shares, as the new company has a lot of access to the weight loss drug market – one forecast will turn to $ 100 billion over the years.
Wall Street is optimistic about Viking prospects, and the average price forecast predicts that the stock price will increase by approximately 240% today. Of course, Viking is highly dependent on the results of these tests, so it is at some risk – but the data has been strong, so growth investors may want to enter Viking so that potentially announce a great victory later.
CRISPR therapy(Nasdaq: CRSP) The shares grew in the year, which made the main stage: the first approval of its product. However, since last year, the Casgevy, which has been treated with genes for blood disorders, has decreased. Sometimes investors buy shares well before the company wins confirmation or by spending the product, then captures profits after good news lands – and I think that’s exactly what happened here.
Ycharts CRSP data
But what it does, gives us the opportunity to get at a very good price for a promising company that can provide fantastic news. Casgevy, as a gene editing treatment, takes a longer time to lift than a tablet or injection as this includes several steps that take place within months. Recently, the company said that this year new patients’ initiations should increase “significantly” – there is reason to optimistically optimistic to evaluate the growth of inflows.
CRISPR therapy has also recently reported positive Phase 1 data on gene editing a candidate solved high cholesterol. And the company expects to report data soon from a phase 1 study involving a candidate directed at patients with increased lipoprotein levels (A) – a risk factor for cardiovascular disease. This could be the huge CRISPR therapy market if the candidates reach the finish line, and in the meantime any possible positive news could increase the promotions.
The company also hopes for other tests on oncology and autoimmune diseases this year – so this biotechnology calendar is rich in potential catalysts.
The average Wall Street prognosis requires CRISPR therapy to receive 84 percent of today’s price.
Before buying Viking Therapeutics stock, consider this:
Motley Fool Stock Advisor A team of analysts just found what they think is 10 best stocks To buy investors now … and Viking Therapeutics was not one of them. 10 stocks that reduced the incision can return the monster in the coming years.
Consider whenNetflixThis list consisted of 2004. December 17th … If you have invested $ 1,000 during our recommendation, at our recommendation,You would have $ 664 089!* Or when NvidiaMade this list in 2005. April 15 … If you have invested $ 1,000 during our recommendation, at our recommendation,You would have $ 881,731!*
Now it is worth mentioningShare advisorThe total average return is994%— the advantage of the chink of a chick compared to172%S&P 500. Don’t miss the latest top 10 list that you can find by logging inShare advisor;
See. 10 stocks »
*The stock advisor returns from 2025. June 9th
Adria Cimino has no position in any of the above shares. Motley fools hold positions and recommend Crispr Therapeutics. Motley fool recommends Viking Therapeutics. The Motley fool has a disclosure policy.
According to some Wall Street analysts, The Motley Fool initially released The Motley Fool, initially released 2 biotechnology shares that can be acquired by 84% and 240%.
